"What should they be doing
is scenario planning and being prepared for the best or worst and everything in
between. If biosimilars are not available, this could impact payers that have
them on formulary should a disruption occur in their marketing."
— F. Randy Vogenberg, Ph.D., principal at the Institute for
Integrated Healthcare, talked with AIS's RADAR
on Specialty Pharmacy about how the Supreme Court's forthcoming
ruling on the Affordable Care Act could affect the biosimilars market.
Subscribers may read the RADAR on Specialty Pharmacy article in which this quote appeared online. Learn more about subscribing to AIS Health's publications.
No comments:
Post a Comment